Business Wire

CGTN: Xi Jinping Reviews Poverty Relief Progress in Hunan as China's War on Poverty Nears End

Share

China has vowed to eradicate absolute poverty in rural areas by the end of 2020 despite the COVID-19 epidemic. While efforts are being made to ensure "no single poor area or individual shall be left behind" – as President Xi Jinping puts it – people that have recently shaken off poverty are striving for a better life.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005399/en/

Among the 529 residents in a small village in central China's Hunan Province, 95 in 30 households used to live under the poverty line. The whole village was lifted out of poverty through rural tourism in 2018, and the average annual income of the residents reached 13,840 yuan (about 2,060 U.S. dollars) last year – way above the national poverty line of 2,300 yuan (about 340 U.S. dollars).

Shazhou Village, located in a mountainous area in Rucheng County, Chenzhou City, was the first stop of Xi's inspection tour in Hunan.

Xi, also general secretary of the Communist Party of China (CPC) Central Committee, visited the village on Wednesday and learned about poverty relief industries and progress in consolidating poverty eradication at a modern agricultural tourism demonstration base.

Targeted poverty alleviation

China has adopted a targeted approach in its poverty alleviation campaign, which means taking tailored relief measures to fit different local conditions.

The story of Shazhou is a prime example of that approach. The village boasts the beautiful scenery of the Luoxiao Mountains and the unique Yao ethnic culture – nearly two thirds of the residents belong to the Yao ethnic group. Tourism has played a significant role in Shazhou's battle against poverty.

The village has promoted rural tourism and high-quality fruit planting, and arranged training programs to help villagers obtain such job skills as for restaurant cooks and rural tourism industry employees. More than 350 local jobs have been created through the efforts.

With all its residents lifted out of poverty, Shazhou has also been known for such national-level honor as the "village of beauty and leisure," "role model for ethnic unity and progress," "key village for promoting rural tourism" and "traditional Chinese village."

New starting point

Since the 18th CPC National Congress in late 2012, China has achieved remarkable results in poverty reduction. More than 93 million rural people shook off poverty between 2013 and 2019.

But 5.51 million people needed to get rid of poverty by the end of 2019. And such a formidable task was coincided by accident with the coronavirus outbreak.

Speaking at a symposium on poverty alleviation in March, Xi described the goal of ending absolute poverty by 2020 as a "solemn pledge" made by the CPC Central Committee to the Chinese people, urging authorities at all levels to deliver on that promise.

As China intensifies efforts in the final stage of the tough battle, Xi tours around the country to inspect economic and social development, with poverty alleviation high on the agenda. Prior to the Hunan trip, he had taken inspection tours this year of capital city Beijing and provinces of Yunnan, Hubei, Zhejiang, Shaanxi, Shanxi, Jilin and Anhui, and Ningxia Hui Autonomous Region.

In addition to increasing poor people's incomes, China is also striving to improve the quality of poverty relief. Xi has repeatedly called for efforts to ensure rural poor people do not have to worry about food and clothing and have access to compulsory education, basic medical services and safe housing.

Meanwhile, he is looking into the future beyond the end of poverty. "Being lifted out of poverty is not an end in itself but the starting point of a new life and a new pursuit," he said on several occasions this year, calling for consolidating achievements in poverty alleviation and advancing the rural vitalization strategy.

Put forward at the 19th CPC National Congress in 2017, the strategy aims to build rural areas with thriving businesses, pleasant living environments, social etiquette and civility, effective governance and prosperity.

Shazhou is among many previously poor villages in China that have embarked on the journey for a better future.

On Wednesday, Xi also visited a revolution-themed exhibition hall, a village service center, a clinic, a primary school and the homes of villagers in Shazhou.

Contact information

Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx ® (cabozantinib) in Combination With Opdivo ® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 18:30:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen